Lv2
110 积分 2024-07-02 加入
Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?
3个月前
已完结
Implications of ligand-receptor binding kinetics on GLP-1R signalling
10个月前
已完结
Prolonged Activation of the GLP-1 Receptor via Covalent Capture
10个月前
已完结
At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide
11个月前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
11个月前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
11个月前
已完结
皖公网安备34019202002308
